Compare · LMRI vs NTRA
LMRI vs NTRA
Side-by-side comparison of Lumexa Imaging Holdings Inc. (LMRI) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LMRI and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $30.84B, about 37.8x LMRI ($816.7M).
- Over the past year, LMRI is down 56.6% and NTRA is up 31.5% - NTRA leads by 88.1 points.
- NTRA has been more active in the news (16 items in the past 4 weeks vs 3 for LMRI).
- NTRA has more recent analyst coverage (25 ratings vs 9 for LMRI).
- Company
- Lumexa Imaging Holdings Inc.
- Natera Inc.
- Price
- $8.03-5.64%
- $215.88+0.26%
- Market cap
- $816.7M
- $30.84B
- 1M return
- -21.43%
- -1.72%
- 1Y return
- -56.62%
- +31.52%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2015
- News (4w)
- 3
- 16
- Recent ratings
- 9
- 25
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest LMRI
- Lumexa Imaging Announces Joint Venture with Hospital for Special Surgery (HSS) to Expand Advanced Outpatient Imaging in New York
- Director Brodnax Brett bought $253,750 worth of shares (35,000 units at $7.25), increasing direct ownership by 130% to 62,027 units (SEC Form 4)
- Director Cooper Henry Lee bought $223,113 worth of shares (30,000 units at $7.44) (SEC Form 4)
- SEC Form 10-Q filed by Lumexa Imaging Holdings Inc.
- Lumexa Imaging Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Lumexa Imaging Announces First Quarter 2026 Results
- Lumexa Imaging Advances Growth Strategy by Adding Four New Imaging Centers
- SEC Form DEFA14A filed by Lumexa Imaging Holdings Inc.
- SEC Form DEF 14A filed by Lumexa Imaging Holdings Inc.
- Lumexa Imaging Announces First Quarter 2026 Earnings Conference Call Date
Latest NTRA
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)
- Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
- SEC Form 144 filed by Natera Inc.
- Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma